PATENT/OFFICIAL

SHEET <u>1</u> OF <u>1</u>

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)			SRL-001IIS	ATTY. DOCKET NO. SBL-001US		SERIAL NO. 09/892,613	
			APPLICANT Shawn Shui-on LEUNG				
			FILING DATE June 27, 2001			643	
		U.S. PATENT D	OCUMENTS				
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
EXAMINER'S INITIALS	PATENT NO.	DATE COU	NTRY/APPLICANT	CLASS	SUBCLASS	Translation Yes No	
	OTHER	ART (Including Author, 1	litle, Date, Pertinen	t Pages, Etc.)	<u> </u>	
/DB/	Fiona ADAIR, "Immunogenicity: The Last Hurdle for Clinically Successful Therapeutic Antibodies", <i>BioPharm</i> , pp. 42-46 (October 2000). Man Sung CO et al., "Humanized Antibodies for Antiviral Therapy", <i>PNAS USA</i> , Vol. 82 2869-2973 (April 1991).						
	Elvin A. KABAT et al., "Identical V Region Amino Acid Sequences and Segment of Sequences in Antibodies of Different Specificities", <i>Journal of Immunology</i> , Vol. 1 1709-1719 (September 1991). Eduardo A. PADLAN, "Anatomy of the Antibody Molecule", <i>Molecular Immunology</i> , 31 (3): 169-217 (1994).						
/DB/	Tai Te WU et al., "Possible Use of Similar Framework Region Amino Acid Sequences Between Human and Mouse Immunoglobulins for Humanizing Mouse Antibodies", <i>Molecular Immunology</i> , Vol. 29 (9): 1141-1146 (1992).						
}							
EXAMINER	/David Bland	chard/	DATE CONSIDERI	ED 08/16	/2007		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

PTO/SB/08B (02-03)
Approved for use through 04/30/2003. OMB 0651-0031

Unt	er the Peperwork Rec	tuction A	ct of 1995, no persons a	re required to respond to a collection	of Information unless it contains a valid OMB control	number.	
Substitute for form 1449/PTO				Complete if Known			
				Application Number	09/892,613		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	June 27, 2001		
			PPLICANT	First Named Inventor	Shawn Shui-on LEUNG		
(Use as many sheets as necessary)				Art Unit	1642		
,				Examiner Name	David Blanchard		
Sheet	1	of	1	Attorney Docket Number	655-US		

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
DB	1	Complaint for Declaratory Judgment and Permanent Injunction (Civil Action No. 2471-N), including Exhibits A-G	
- DB	2	Motion for Special Process Servers (Civil Action No. 2471-N), and Order Appointing Special Process Servers (Civil Action No. 2471-N)	
DB	3	Supplemental Information Pursuant to Rule 3(a) of the Rules of the Court of Chancery	

l Examiner		Date	
	/	I Date 1	10/11/0000
Signature	/David Blanchard/	Considered	12/11/2006
0.9.10.010	,	Considered	,,,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Transiation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Transiation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Transiation is attached.

1 This collection of Information is required to optionally support of the process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the complete deplication form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your equire to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: